🟢 Outlook Therapeutics is trading 5.1% up today as dilution overhang clears ahead of FDA decision

Outlook Therapeutics is trading 5.1% up at $1.45 as shares rebound from recent dilution-related selling pressure.

• The stock had been weighed down following a July 17 filing to register approximately 17.3 million existing shares for resale, but buyers are returning as the supply is absorbed.
• Market focus is shifting back to the upcoming July 29 FDA decision date for LYTENAVA, which remains the company's primary fundamental catalyst.
• Shares are recovering lost ground as investors position themselves ahead of the critical regulatory milestone.